Results 21 to 30 of about 411,617 (199)

Evaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes

, 2021
The incidence of type 1 diabetes in children is growing and optimal treatment is needed to prevent or delay complications. Insulin degludec is a new basal insulin with ultra-long effect.
Sellbom, Malin, Malin Sellbom, Charlotta Nilsson, Nilsson, Charlotta   +3 more
core   +1 more source

DUAL I China:在一项对未服用口服降糖药物的中国2型糖尿病患者进行的随机试验中, IDegLira与其单独成分相比改善了血糖控制

Journal of Diabetes, 2022
Background DUAL I China, one of the DUAL trials, assessed efficacy/safety of insulin degludec/liraglutide (IDegLira) in Chinese adults with type 2 diabetes (T2D) not controlled by oral antidiabetic drugs (OADs).
Weiqing Wang, Bue F. Ross Agner, Bin Luo, Lei Liu, Ming Liu, Yongde Peng, Shen Qu, Karolina Amelia Stachlewska, Guixia Wang, Guoyue Yuan, Qiu Zhang, Guang Ning   +11 more
doaj   +1 more source

National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment

Сахарный диабет, 2014
In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes.
Gagik Radikovich Galstyan
doaj   +1 more source

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design

BMC Endocrine Disorders, 2019
Background Hypoglycaemia, especially nocturnal, remains the main limiting factor of achieving good glycaemic control in type 1 diabetes. The effect of first generation long-acting insulin analogues in reducing nocturnal hypoglycaemia is well documented ...
Rikke Mette Agesen, Amra Ciric Alibegovic, Henrik Ullits Andersen, Henning Beck-Nielsen, Peter Gustenhoff, Troels Krarup Hansen, Christoffer Hedetoft, Tonny Jensen, Claus Bogh Juhl, Susanne Søgaard Lerche, Kirsten Nørgaard, Hans-Henrik Parving, Lise Tarnow, Birger Thorsteinsson, Ulrik Pedersen-Bjergaard   +14 more
doaj   +1 more source

Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system

Endocrinology, Diabetes & Metabolism Case Reports, 2018
An adolescent with type 1 diabetes and a history of self-harm, which included intentional overdoses and insulin omission, presented with an insulin degludec overdose.
Harmony Thompson, Helen Lunt, Cate Fleckney, Steven Soule   +3 more
doaj   +1 more source

Retrospective trial of long acting analogues detemir and degludec usage in children and adolescents to overcome glucose variability caused by dawn phenomenon and reverse dawn phenomenon

Сахарный диабет, 2021
Backgraund: Children with type 1 diabetes mellitus (T1DM) need more insulin late in the evening (reverse dawn phenomenon (RDP)), and adolescents need more insulin yearly in the morning (dawn phenomenon (DP)); these cause blood glucose variability. Modern
A. V. Vitebskaya, E. V. Shreder, A. V. Popovich, E. A. Pisareva   +3 more
doaj   +1 more source

Use of insulin degludec in pregnancy: two case reports and a literature review

Endocrine and Metabolic Science, 2020
As of now, insulin Degludec has no indication for use in pregnancy, because of the lack of studies that prove its safety for foetus. However it isn't infrequent that some women conceive while treating with insulin Degludec.
E. Sprio, P. Lucotti, C. Iadarola, C. Bellingeri, F. Beneventi, E. Lovati   +5 more
doaj   +1 more source

Long-acting insulin allergy in a diabetic child

International Journal of Immunopathology and Pharmacology, 2017
Insulin allergy has been uncommon since the introduction of human recombinant insulin preparations; the prevalence is 2.4%. Insulin injection could elicit immediate reactions, which are usually induced by an IgE-mediated mechanism, within the first hour ...
Carla Mastrorilli, Laura Rizzuti, Antonina Marta Cangelosi, Brunella Iovane, Giovanni Chiari, Carlo Caffarelli   +5 more
doaj   +1 more source

Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia [PDF]

, 2023
Aim: To compare nocturnal glucose profiles according to hourly plasma glucose measurements during treatment with insulin degludec and insulin glargine U100 in a cohort of people with type 1 diabetes prone to nocturnal severe hypoglycaemia.
Lise Tarnow, Tonny Jensen, Andersen, Henrik Ullits, Henrik Ullits Andersen, Juhl, Claus Bogh, Thorsteinsson, Birger, Hans‐Henrik Parving, Hansen, Troels Krarup, Beck-Nielsen, Henning, Brøsen, Julie Maria Bøggild, Rikke Mette Agesen, Parving, Hans-Henrik, Julie Maria Bøggild Brøsen, Peter Gustenhoff, Lerche, Susanne Søgaard, Parving, Hans Henrik, Ulrik Pedersen‐Bjergaard, Jensen, Tonny, Henning Beck‐Nielsen, Susanne Søgaard Lerche, Pedersen-Bjergaard, Ulrik, Charlotte Røn Stolberg, Peter Lommer Kristensen, Stolberg, Charlotte Røn, Birger Thorsteinsson, Kristensen, Peter Lommer, Kirsten Nørgaard, Tarnow, Lise, Agesen, Rikke Mette, Gustenhoff, Peter, Troels Krarup Hansen, Christoffer Hedetoft, Hedetoft, Christoffer, Claus Bogh Juhl, Amra Ciric Alibegovic, Alibegovic, Amra Ciric, Nørgaard, Kirsten   +36 more
core   +1 more source

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes

Diabet. Med. 29, 716720 (2012) Abstract Aims The efficacy and safety of insulin degludec (degludec), a new-generation ultra-long-acting basal insulin, was compared with insulin glargine (glargine) in people with Type 1 diabetes mellitus in a 16-week ...
Jendle J, Ratner RE, Roberts AP, Meneghini L, Johansen T, Christensen TE, Home PD, Birkeland KI, Wendisch U   +8 more
core   +5 more sources